Enveda is a biotechnology company that is learning from life’s chemistry to create better medicines faster. Enveda uses AI-powered tools to identify and characterize a wide range of molecules produced by living organisms—the vast majority of which have never been explored by science—creating a database of chemical biodiversity: the library of life. By growing, organizing, translating, and searching this unique library, Enveda learns from life’s evolved solutions to address today’s pressing medical needs. For more information on Enveda, visit enveda.com.
Location: United States
Total raised: $430M
Investors 1
| Date | Name | Website |
| 29.12.2024 | Wireframe ... | wireframev... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 11.09.2025 | Series D | $150M | IA Venture... |
| 07.03.2025 | Series C | $150M | - |
| 21.11.2024 | Series C | $130M | - |
Mentions in press and media 15
| Date | Title | Description |
| 06.01.2026 | Musk’s AI chatbot faces global backlash over sexualized images of women and children | Getting your Trinity Audio player ready... By KELVIN CHAN, AP Business Writer LONDON (AP) — Elon Musk’s AI chatbot Grok is facing a backlash from governments around the world after a recent surge in sexualized images of women and children g... |
| 11.09.2025 | Enveda: $150 Million Series D Raised To Advance Clinical Trials And Enhance Leadership | Enveda, a clinical-stage biotechnology company focused on developing a new generation of small-molecule drugs sourced from nature, has announced a significant milestone with the close of its $150 million Series D funding round. The round wa... |
| 04.09.2025 | Enveda Raises $150M in Series D Funding | Enveda, a Boulder, CO-based clinical-stage biotech company, raised $150M in Series D funding. The round was led by Premji Invest with participation from new and existing investors Baillie Gifford, Kinnevik, Lingotto Investment Management, P... |
| 07.03.2025 | Enveda: $150 Million (Series C) Raised For Creating Better Medicines Faster | Enveda, a leading biotechnology company utilizing life’s chemistry to discover better medicines, today announced an investment from Sanofi, a leading healthcare company. This funding reaffirms the industry’s confidence in Enveda’s drug disc... |
| 01.03.2025 | PU Prime: A Beacon of Innovation in Multi-Asset Trading | In the bustling world of finance, where competition is fierce and innovation is key, PU Prime has emerged as a standout player. Recently awarded the title of Best Multi-Asset Broker – MEA 2025 at the prestigious iFX EXPO Dubai, this Singapo... |
| 27.02.2025 | PU Prime Wins Best Multi-Asset Broker – MEA 2025 at iFX EXPO Dubai | Singapore, Singapore, February 11th, 2025, FinanceWire PU Prime has been recognized Best Multi-Asset Broker – MEA 2025 at a ceremony held at the Dubai World Trade Centre. The award was presented at the close of the first day of iFX EXPO Dub... |
| 27.02.2025 | Enveda Receives Investment from Sanofi; Brings Total Series C Financing to $150M | Enveda, a Boulder, CO-based biotechnology company empowering life’s chemistry to discover new medicines, received an investment from Sanofi, bringing the total of Series C funding to $150M. Envada had announced a $130M Series C funding in N... |
| 17.01.2025 | Recent Digital Health Executive Hires and Promotions: Medidata Expands Team, CareRev, Philips, Eko Health, Others | AVIZVA, a health-tech organization that offers a variety of solutions for healthcare enterprises, that it has appoints James Vertino as its new CEO. Model N appoints Bret Connor as Chief Executive Officer. The Board of Directors of Blue Shi... |
| 24.11.2024 | Enveda: $130 Million (Series C) Raised To Translate Nature Into New Medicines | Enveda – a biotechnology company using AI to translate nature into new medicines – announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV with participation from new and existing investors Baillie Gifford, P... |
| 21.11.2024 | Enveda raises $130M series C to take more AI-discovered compounds into the clinic | Enveda, a company using artificial intelligence to boost nature-based drug discovery, is envisioning clinical success with a $130 million series C fundraising round. The round was led by Kinnevik and FPV with other new and existing investor... |
Show more